Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02388906 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
A Phase 3 study of Melanoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 906
- Enrollment target
- 20
- Study locations
NCT02388906: Completed Phase 3 study of Melanoma, sponsored by Bristol-Myers Squibb.
NCT02388906 is a Phase 3 study of Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 906 participants, above the 703-participant average among 266 other Melanoma trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02388906, a Phase 3 study of Melanoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 906 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
Primary Outcome
RFS is defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma, or death (whatever the cause), whichever occurs first.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- OTHER Placebo matching Ipilimumab
- OTHER Placebo matching Nivolumab
Study Locations (20)
California
- Local Institution - 0117 - La Jolla
- Local Institution - 0189 - Los Angeles
- Local Institution - 0021 - San Francisco
- Local Institution - 0006 - San Francisco
Florida
- Local Institution - 0012 - Jacksonville
- Local Institution - 0019 - Miami Beach
- Local Institution - 0030 - Orlando
- Local Institution - 0032 - Tampa
Massachusetts
- Local Institution - 0013 - Boston
- Local Institution - 0170 - Boston
- Local Institution - 0171 - Boston
Arkansas
- Local Institution - 0036 - Little Rock
Colorado
- Local Institution - 0010 - Aurora
District of Columbia
- Local Institution - 0004 - Washington D.C.
Georgia
- Local Institution - 0016 - Atlanta
Illinois
- Local Institution - 0106 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 906 participants |
| Start Date | 2015-03-16 |
| Est. Completion | 2024-10-16 |
| Phase | Phase 3 |
What the finished NCT02388906 record still lists
NCT02388906 is an interventional study that assigns participants to a tested intervention. The registered 906 participants enrollment target is mid-sized for trials with a published cap, above the 703-participant average among 266 other Melanoma trials with a reported enrollment target (29% higher).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT02388906 names 20 study sites across 12 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02388906 about?
NCT02388906 is a clinical study titled "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma". The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
What is the current status of trial NCT02388906?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 906 participants. The study started on 2015-03-16. Estimated completion is 2024-10-16.
What conditions does trial NCT02388906 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT02388906?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Placebo matching Ipilimumab (OTHER), Placebo matching Nivolumab (OTHER).
Who is sponsoring clinical trial NCT02388906?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02388906 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02388906's enrollment target sits among peer trials
906 24th of 266 higher than 243 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RECRUITING · Phase 3
-
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 3
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI